跳至內容

烏美溴銨/維蘭特羅

維基百科,自由的百科全書
烏美溴銨/維蘭特羅
烏美溴銨(上方)和維蘭特羅(下方)
組成
烏美溴銨毒蕈鹼拮抗劑英語Muscarinic antagonist
維蘭特羅超長效β2激動劑英語Long-acting beta-adrenoceptor agonist
臨床資料
商品名英語Drug nomenclatureAnoro Ellipta、Laventair Ellipta
AHFS/Drugs.com專業藥物信息
核准狀況
懷孕分級
給藥途徑吸入給藥
ATC碼
法律規範狀態
法律規範
識別資訊
CAS號2446159-58-4
KEGG

烏美溴銨/維蘭特羅(英語:umeclidinium bromide/vilanterol;商品名:Anoro Ellipta等),是一種用於治療慢性阻塞性肺病 (COPD) 的固定劑量複方藥物。[4][5]它通過吸入給藥

最常見的副作用包括上呼吸道感染尿路感染咽炎鼻竇炎鼻咽炎、頭痛、咳嗽、口咽疼痛、便秘和口乾。[3]

2021年,它是美國第212位最常用處方藥物,處方數量超過200萬張。[6][7]

參考資料

  1. ^ Prescription medicines: registration of new chemical entities in Australia, 2014. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023]. (原始內容存檔於2023-04-10). 
  2. ^ Anoro Ellipta 55 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC). (emc). 7 October 2019 [29 October 2020]. (原始內容存檔於2021-08-29). 
  3. ^ 3.0 3.1 Anoro Ellipta EPAR. European Medicines Agency (EMA). 17 September 2018 [28 October 2020]. (原始內容存檔於2020-11-11).  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. ^ Feldman GJ, Edin A. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Therapeutic Advances in Respiratory Disease. December 2013, 7 (6): 311–9. PMID 24004659. S2CID 5744282. doi:10.1177/1753465813499789. 
  5. ^ FDA Approves Umeclidinium and Vilanterol Combo for COPD. Medscape. 18 December 2013 [2024-03-07]. (原始內容存檔於2017-09-24). 
  6. ^ The Top 300 of 2021. ClinCalc. [14 January 2024]. (原始內容存檔於15 January 2024). 
  7. ^ Umeclidinium; Vilanterol - Drug Usage Statistics. ClinCalc. [14 January 2024]. (原始內容存檔於2024-02-29).